Decitabine: all 314 studies that test it
Page 3 of 4. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young AdultsCompletedNCT03445858Early Phase 1
- A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AMLStatus unknownNCT03417427Phase 2
- Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic SyndromeTerminatedNCT03404193Phase 2
- Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 MutationsStatus unknownNCT03381781Phase 2
- DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast ExcessStatus unknownNCT03356080Phase 2
- Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsStatus unknownNCT03346642Phase 1/2
- Decitabine Plus Carboplatin in the Treatment of Metastatic TNBCTerminatedNCT03295552Phase 2
- Clinical Study of Decitabine and Paclitaxel Combination TherapyStatus unknownNCT03282825Phase 1
- Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITPStatus unknownNCT03252457Phase 3
- Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCLActive, not recruitingNCT03240211Phase 1
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03164057Phase 2
- Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaActive, not recruitingNCT03132454Phase 1
- The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal KaryotypeStatus unknownNCT03080766Phase 2
- Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDSCompletedNCT03066648Phase 1
- STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive ChemotherapyCompletedNCT03063944Phase 1
- Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion DependentStatus unknownNCT03045510Phase 2
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT03041688Phase 1
- Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)Status unknownNCT03026842Phase 4
- Efficacy of Decitabine in Clearance of MRDWithdrawnNCT03021395Phase 1/2
- Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingNCT03017131Phase 1
- Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid LeukemiaCompletedNCT03009240Phase 1
- Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid LeukemiaStatus unknownNCT02985372Phase 3
- Decitabine and Gemcitabine for Pancreatic Cancer and SarcomaCompletedNCT02959164Phase 1
- Decitabine Plus R-CHOP in Diffuse Large B-cell LymphomaStatus unknownNCT02951728Phase 1/2
- p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic CancerCompletedNCT02847000Early Phase 1
- p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid MalignanciesCompletedNCT02846935Early Phase 1
- A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)Status unknownNCT02779569Not applicable
- G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCTCompletedNCT02744742Phase 2/3
- Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic CancerStatus unknownNCT02685228Not applicable
- Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AMLCompletedNCT02662647Phase 2
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory MalignanciesCompletedNCT02499861Phase 1/2
- Epigenetic Reprogramming in Relapse AMLTerminatedNCT02412475Phase 1
- Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02316964Phase 1
- Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)CompletedNCT02316028Phase 1/2
- Phase I, Dose Escalation Study of DecitabineCompletedNCT02264873Phase 1
- 10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1CompletedNCT02252107Phase 2
- Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60TerminatedNCT02234037Phase 1
- Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMMLCompletedNCT02214407Phase 3
- A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02204085Phase 1/2
- Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)TerminatedNCT02203773Phase 1
- "InDACtion" vs "3+7" Induction in AMLStatus unknownNCT02172872Phase 3
- Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary CancerStatus unknownNCT02159820Phase 2/3
- Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)TerminatedNCT02141477Phase 1
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
- Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT02093403Phase 1
- Study of Molecular and Genetic Abnormalities in Patients With Myeloid NeoplasmsCompletedNCT02084563Phase 2
- Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLCompletedNCT02076191Phase 1/2
- Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid LeukemiaStatus unknownNCT02072811Phase 3
- A Phase Ⅳ Study of Decitabine in Myelodysplastic SyndromeStatus unknownNCT02013102Phase 4
- Pre-operative Decitabine in Colon Cancer: a Proof of Principle StudyTerminatedNCT01882660Not applicable
- Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus CobimetinibTerminatedNCT01876641Phase 1
- Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01861314Phase 1
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid LeukemiaCompletedNCT01834248Phase 1
- Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeStatus unknownNCT01809392Phase 2/3
- Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell TransplantationStatus unknownNCT01806116Phase 4
- Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell LymphomasStatus unknownNCT01799083Phase 1/2
- AR-42 and Decitabine in Treating Patients With Acute Myeloid LeukemiaCompletedNCT01798901Phase 1
- Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell TransplantationStatus unknownNCT01758367Phase 1/2
- Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）CompletedNCT01690507Phase 1/2
- Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell DiseaseCompletedNCT01685515Phase 1
- Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerCompletedNCT01673217Phase 1
- Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia PatientsStatus unknownNCT01633099Phase 3
- Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaActive, not recruitingNCT01627041Phase 2
- A Multi-center Study of Low-dose Decitabine for the Treatment of Immune ThrombocytopeniaCompletedNCT01568333Phase 2
- Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT01567059Phase 2
- PRO#0118: Decitabine Plus Mini Flu-BuCompletedNCT01455506Phase 1
- Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)CompletedNCT01352650Phase 1
- Study of Decitabine Induction Prior to Allogeneic Hematopoietic Cell Transplant in Newly Diagnosed MDS PatientsTerminatedNCT01333449Phase 2
- Dose Finding Study of Post-BMT Decitabine Maintenance Treatment in Higher-risk MDS and MDS/AMLStatus unknownNCT01277484Phase 1
- Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic LeukemiaCompletedNCT01251627Phase 2
- Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)Status unknownNCT01211457Phase 1/2
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia PatientsCompletedNCT01149408Phase 1
- Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) FailureStatus unknownNCT01133886Phase 2
- Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid LeukemiaCompletedNCT01130662Phase 1
- Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT01130506Phase 1
- Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)CompletedNCT01098084Phase 2
- Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)CompletedNCT01001143Phase 1
- Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post TransplantCompletedNCT00986804Phase 1
- Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)CompletedNCT00941109Phase 1
- 5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular CorrelatesTerminatedNCT00886457Phase 1
- KRAS Wild-type Metastatic Colorectal Cancer TrialCompletedNCT00879385Phase 1
- Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid LeukemiaCompletedNCT00866073Phase 2
- A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00861874Phase 1
- Lenalidomide and Decitabine in High Grade Myelodysplastic SyndromesCompletedNCT00828802Phase 1
- Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I PortionTerminatedNCT00791271Phase 1
- Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00748527Phase 2
- Decitabine and Bortezomib in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00703300Phase 1
- Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid LeukemiaCompletedNCT00671697Phase 1
- Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AMLCompletedNCT00538876Phase 1
- Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other DiseasesCompletedNCT00357708Phase 1
- A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)CompletedNCT00349596Phase 1
- A Clinical Trial of Decitabine in Patients With Myelodysplastic SyndromeTerminatedNCT00282399Phase 1
- Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersCompletedNCT00114257Phase 1
- Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
- Decitabine in Treating Patients With Advanced Refractory Solid Tumors or LymphomasTerminatedNCT00089089Phase 1
- Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung CancerCompletedNCT00084981Phase 1
- Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00079378Phase 1
- Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or NeuroblastomaCompletedNCT00075634Phase 1